Track 21: HIV gene therapy

In patients with HIV, highly active antiretroviral therapy significantly increases survival. The existence of drug-resistant escape mutations, cumulative toxicities, and partial immunological recovery can make lifelong treatment more difficult as a result of the persistence of HIV in reservoirs. In the absence of long-term antiviral medication, cell and gene therapies hold the potential of avoiding progressive HIV infection by blocking HIV replication.


    Related Conference of Track 21: HIV gene therapy

    November 17-18, 2025

    18th International Conference on Human Genomics and Genomic Medicine

    Paris, France
    March 09-10, 2026

    21th World Congress on Tissue Engineering Regenerative Medicine and Stem Cell Research

    Singapore City, Singapore
    April 16-17, 2026

    19th World Congress on Stem Cell Research

    Tokyo, Japan
    April 23-24, 2026

    9th Annual Conference on Stem Cell and Regenerative Medicine

    Dubai, UAE
    May 04-05, 2026

    14th World Congress on Human Genetics and Genetic Diseases

    Paris, France
    May 25-26, 2026

    20th International Conference on Regenerative Repair and Medicine

    Madrid, Spain
    June 08-09, 2026

    9th Global Conference on Cell and Gene Therapy

    Rome, Italy
    June 15-16, 2026

    22nd Global Summit on Stem Cell & Regenerative Medicine

    Amsterdam, Netherlands
    June 15-16, 2026

    13th World Congress on Epigenetics and Chromosome

    Paris, France
    June 18-19, 2026

    16th International Conference on Human Genetics and Genetic Diseases

    Singapore City, Singapore
    June 18-19, 2026

    19th International Conference on Genomics & Pharmacogenomics

    Singapore City, Singapore
    September 25-26, 2025

    6th Annual summit on Cell Signaling and Cancer Therapy

    Montreal, Canada

    Track 21: HIV gene therapy Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in